

**INDICATION:**

HER2 positive: Neoadjuvant or Adjuvant

REFERENCES:

1. [NCCN Guidelines® for Breast Cancer V.1.2017.](#)
2. [Slamon D, et al. N Engl J Med. 2011;365\(14\):1273-83.a](#)
3. [Joensuu H, et al. N Engl J Med. 2006;354\(8\):809-20.a](#)

NCCN SUPPORTIVE CARE:

1. *Emetic risk:* Day 1 High
2. *Febrile Neutropenia Risk:* Intermediate

CHEMOTHERAPY REGIMEN

21-day cycle for 4 cycles

- **DOXOrubicin** 60 mg/m² IV push on Day 1
 - See *Safety Parameters and Special Instructions* for information on slow IV Push administration.
- **Cyclophosphamide** 600 mg/m² IV over 30 minutes on Day 1
 - Oral hydration is strongly encouraged with cyclophosphamide; poorly hydrated patients may need supplemental IV hydration. Patients should attain combined oral and IV hydration of 2000 – 3000 mL/day on day of chemotherapy.
See *Other Supportive Therapy* for example of IV hydration.

This course is 4 cycles of AC (DOXOrubicin and cyclophosphamide) Every 21 Days, DOCEtaxel Every 21 Days and Trastuzumab course is initiated following completion of this course. Please see Order Template BRS27b for DOCEtaxel Every 21 Days and Trastuzumab course.

SUPPORTIVE CARE**Antiemetic Therapy**

Scheduled prophylactic antiemetic therapy should be given for prevention of acute and delayed nausea and vomiting based on the emetic risk of the chemotherapy regimen. This may include antiemetic therapy given on the days following chemotherapy. For more information on emetic prophylaxis, refer to the [NCCN Guidelines for Antiemesis](#) and [Appendix D](#) to the NCCN Chemotherapy Order Templates.

PRN for breakthrough: All patients should be provided with at least one medication for breakthrough emesis. Please consult the [NCCN Guidelines for Antiemesis](#) for appropriate antiemetic therapy.

Myeloid Growth Factor Therapy

- CSFs may be considered for primary prophylaxis based on the febrile neutropenia (FN) risk of the chemotherapy regimen. For more information on prophylaxis of FN, refer to [NCCN Guidelines for Myeloid Growth Factors](#) and [Appendix C](#) to the NCCN Templates.

Other Supportive Therapy

- For cyclophosphamide: *Example of recommended hydration:* Sodium chloride 0.9% infused IV at a rate of 1.5 – 3 mL/kg/hour for a total of 500 mL on day of chemotherapy.

MONITORING AND HOLD PARAMETERS

- CBC with differential should be monitored as clinically indicated for potential dose modification.
- For DOXOrubicin:
 - Ejection fraction should be monitored prior to initiation of treatment and as clinically indicated.
 - This agent is an anthracycline. Cumulative anthracycline dosage should be monitored.
 - Liver function should be monitored as clinically indicated for potential dose modification or discontinuation.
- For cyclophosphamide: Renal function should be monitored as clinically indicated for potential dose modification or discontinuation.

SAFETY PARAMETERS AND SPECIAL INSTRUCTIONS

- For DOXOrubicin:
 - **This agent is a vesicant.**
 - This agent is administered IV push. The preferred IV push method for a vesicant is administration through the side port of a freely flowing IV; alternatively, the drug can be administered via direct IV push.
 - Secondary malignancies have been associated with this drug. Review drug package insert for additional information.
 - Central venous access is recommended for administration of this agent.
- For cyclophosphamide: Secondary malignancies have been associated with this drug. Review drug package insert for additional information.

NCCN Chemotherapy Order Templates (NCCN Templates®) are peer-reviewed statements of the consensus of its authors derived from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) regarding their views of currently accepted approaches to treatment. An NCCN Template does not constitute an order. Any clinician seeking to treat a patient using the NCCN Templates® is expected to use independent medical judgment in the context of individual clinical circumstances of a specific patient's care or treatment. NCCN disclaims all warranties, express or implied including, without limitation, the implied warranties of merchantability and fitness for a particular purpose. NCCN does not warrant the accuracy, currency, or completeness of the NCCN Templates or make any representation regarding the use or the results of the use of the NCCN Templates in treatment. In no event shall NCCN or its members be liable for any damages including, without limitation, incidental, indirect, special, punitive, or consequential damages arising out of or in connection with the use of the NCCN Templates including, without limitation, loss of life, loss of data, loss of income or profit, losses sustained as a result of any injury to any person, or loss or damage to property or claims of third parties.